Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Case Report.
idiopathic intracranial hypertension (iih)
mogad
multiple sclerosis
myelin oligodendrocyte glycoprotein (mog)
myelin oligodendrocyte glycoprotein (mog) antibodies
myelin oligodendrocyte glycoprotein antibody-associated disease
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
accepted:
06
03
2024
medline:
8
4
2024
pubmed:
8
4
2024
entrez:
8
4
2024
Statut:
epublish
Résumé
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a newly discovered autoimmune demyelinating disorder. The clinical manifestations of MOGAD are divergent but often characterized by inflammatory central nervous system (CNS) deficits such as optic neuritis, encephalitis, or transverse myelitis that predominantly affect the pediatric population. Despite the distinct features often associated with MOGAD, the disease exhibits a diverse range of clinical manifestations, making timely diagnosis and treatment challenging. In particular, distinguishing MOGAD from multiple sclerosis (MS) is important for adequate treatment and the prevention of relapsing disease. In this report, we present a rare case of MOGAD in a 57-year-old male who initially exhibited symptoms of bilateral optic nerve edema and flame hemorrhage. This led to an initial misdiagnosis of pseudotumor cerebri. Serological analysis at a tertiary care center ultimately led to the diagnosis of MOGAD after multiple visits to the ophthalmologist with worsening vision deficits.
Identifiants
pubmed: 38586776
doi: 10.7759/cureus.55652
pmc: PMC10996974
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e55652Informations de copyright
Copyright © 2024, Teru et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.